proprietary antimicrobial agent technologies are of rational design, elegantly simple, and cost effective thus allowing patients of all ages and walks of life to benefit.

Encouraging preclinical testing results have generated enthusiasm that they are on a path to providing value added, life-quality improving solutions for patients requiring implantable medical device therapies, those afflicted by topical infection, inflammation, and secondary tissue loss associated with burn trauma, periodontal disease, and abnormal healing such as with chronic wounds.